OncoMatch/Clinical Trials/NCT07256210
Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation
Is NCT07256210 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Donor-derived Natural Killer Cell for acute myeloid leukemia.
Treatment: Donor-derived Natural Killer Cell — This pilot clinical trial aims to evaluate the feasibility, adverse reactions and maximum tolerated dose of mbIL21 ex vivo-expanded donor-derived NK-cell infusions before and after haploidentical or matched-related hematopoietic stem cell transplantation in a cohort of pediatric and young adult patients with chemorefractory or minimal residual disease (MRD) positive acute leukemia.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Demographics
Prior therapy
Must have received: hematopoietic stem cell transplant — indicated to receive
Patient is indicated to receive allo-HSCT according to actual clinical practice
Cannot have received: cellular therapy including allo-HSCT
Cellular therapy including allo-HSCT within prior 4 months period
Lab requirements
Kidney function
clearance of endogenous creatinine or glomerular filtration rate according to schwarz equation ≥50 ml/min/1,73 m2
Liver function
total bilirubin ≤3 uln except for gilbert's disease, alt/ast ≤3 uln
Cardiac function
left ventricular ejection fraction ≥40%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07256210 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior cellular therapy including allo-HSCT disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 25 years or younger and at least 0 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify